Evidence map›Paper›PMID 30600626›Full record

ArticleWorld psychiatry : official journal of the World Psychiatric Association (WPA)2019

The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials.

Davy Vancampfort, Joseph Firth, Christoph U Correll, Marco Solmi, Dan Siskind, Marc De Hert, Rebekah Carney, Ai Koyanagi, André F Carvalho, Fiona Gaughran and 1 more

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World psychiatry : official journal of the World Psychiatric Association (WPA), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05130853 (Social Cognition Individualized Activities Lab), which is not on this map. Cited by 93 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed, 14 pooled it
19.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05130853 nacompletednot on this mapstarted 2021, after this paper: background citation

Social Cognition Individualized Activities Lab (SoCIAL) for the Training of Social Cognition and Narrative Enhancement in Patients With Schizophrenia: A Randomized Controlled Study to Assess Efficacy and Generalization to Real-life Functioning

TypeinterventionalSponsorUniversity of Campania Luigi VanvitelliRan2021 to 2022Enrolled48ConditionsSchizophrenia, Schizo Affective DisorderArmsSocial Skills and Neurocognitive Individualized Training (SoCIAL), Treatmment-as-usual
3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 14 syntheses or guidelines pooled it, 220 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Exercise to treat psychopathology and other clinical outcomes in schizophrenia: A systematic review and meta-analysis.European psychiatry : the journal of the Association of European Psychiatrists · 2023
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Guideline
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Article
  20. Article

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 8 countries.

Davy VancampfortKU Leuven Department of Rehabilitation Sciences, Leuven, Belgium.
Joseph FirthNICM Health Research Institute, Western Sydney University, Westmead, Australia.
Christoph U CorrellHofstra Northwell School of Medicine Hempstead, New York, NY, USA.
Marco SolmiDepartment of Neurosciences, University of Padua, Padua, Italy.
Dan SiskindMetro South Addiction and Mental Health Service, Brisbane, Australia.
Marc De HertUniversity Psychiatric Centre KU Leuven, Kortenberg, Belgium.
Rebekah CarneyDivision of Psychology and Mental Health, University of Manchester, Manchester, UK.
Ai KoyanagiResearch and Development Unit, Parc Sanitari Sant Joan de Déu, Universitat de Barcelona, Fundació Sant Joan de Déu, Barcelona, Spain.
André F CarvalhoCentre for Addiction and Mental Health, Toronto, Ontario, Canada.
Fiona GaughranSouth London and Maudsley NHS Foundation Trust, London, UK.
Brendon StubbsSouth London and Maudsley NHS Foundation Trust, London, UK.
King's College London · GBKU Leuven · BEUniversity of Manchester · GBCentre for Addiction and Mental Health · CACentro de Investigación Biomédica en Red de Salud Mental · ESThe University of Queensland · AUUniversity of Padua · ITZucker Hillside Hospital · US

Funding

Care South London at King's College Hospital NHS Foundation TrustDepartment of Health ICA-CL-2017-03-001Health Education EnglandMaudsley CharityNational Institute for Health Research (NIHR) ICA-CL-2017-03-001
6 · The paper itself

Abstract

We summarized and compared meta-analyses of pharmacological and non-pharmacological interventions targeting physical health outcomes among people with schizophrenia spectrum disorders. Major databases were searched until June 1, 2018. Of 3,709 search engine hits, 27 meta-analyses were included, representing 128 meta-analyzed trials and 47,231 study participants. While meta-analyses were generally of adequate or high quality, meta-analyzed studies were less so. The most effective weight reduction interventions were individual lifestyle counseling (standardized mean difference, SMD=-0.98) and exercise interventions (SMD=-0.96), followed by psychoeducation (SMD=-0.77), aripiprazole augmentation (SMD=-0.73), topiramate (SMD=-0.72), d-fenfluramine (SMD=-0.54) and metformin (SMD=-0.53). Regarding waist circumference reduction, aripiprazole augmentation (SMD=-1.10) and topiramate (SMD=-0.69) demonstrated the best evidence, followed by dietary interventions (SMD=-0.39). Dietary interventions were the only to significantly improve (diastolic) blood pressure (SMD=-0.39). Switching from olanzapine to quetiapine or aripiprazole (SMD=-0.71) and metformin (SMD=-0.65) demonstrated best efficacy for reducing glucose levels, followed by glucagon-like peptide-1 receptor agonists (SMD=-0.39), dietary interventions (SMD=-0.37) and aripiprazole augmentation (SMD=-0.34), whereas insulin resistance improved the most with metformin (SMD=-0.75) and rosiglitazone (SMD=-0.44). Topiramate had the greatest efficacy for triglycerides (SMD=-0.68) and low-density lipoprotein (LDL)-cholesterol (SMD=-0.80), whereas metformin had the greatest beneficial effects on total cholesterol (SMD=-0.51) and high-density lipoprotein (HDL)-cholesterol (SMD=0.45). Lifestyle interventions yielded small effects for triglycerides, total cholesterol and LDL-cholesterol (SMD=-0.35 to -0.37). Only exercise interventions increased exercise capacity (SMD=1.81). Despite frequent physical comorbidities and premature mortality mainly due to these increased physical health risks, the current evidence for pharmacological and non-pharmacological interventions in people with schizophrenia to prevent and treat these conditions is still limited and more larger trials are urgently needed.

Indexed as

antipsychotic switchingblood pressurebody weightcholesteroldietary interventionsexercise interventionsglucoseinsulinlifestyle counselingmetforminphysical healthpsychosisSchizophreniatopiramatetryglicerides

Identifiers

PMID30600626
PMCPMC6313230
OpenAlexW2907830451

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.